Cingulate

Cingulate EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Cingulate (CING) as of Nov 11, 2026 is -34.80 %. In the previous year, Year-over-Year EBITDA Growth was 31.28 % — a change of -211.23% (lower).

EBITDA Growth YoY

-34.80 %

YoY

-211.23%

Last updated:

Year-over-Year EBITDA Growth of Cingulate is 2025 -34.80 % . Year-over-Year EBITDA Growth of Cingulate was 2024 31.28 % . It decreases by -211.23% lower compared to the previous year.

The Cingulate EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2020
39.18 USD
Jan 1, 2021
-191.94 USD
Jan 1, 2022
15.37 USD
Jan 1, 2023
-30.08 USD
Jan 1, 2024
31.28 USD
Jan 1, 2025
-34.80 USD
The Cingulate EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-34.80 %-211.23%
31.28 %-203.98%
-30.08 %-295.77%
15.37 %-108.01%
-191.94 %-589.85%
39.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Year-over-Year EBITDA Growth of Cingulate is -34.80 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cingulate

All Key Metrics — Cingulate